Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
Wang S, Nademanee A, Qian D, Dagis A, Park HS, Fridey J, Smith E, Snyder D, Somlo G, Stein A, Rosenthal J, Falk P, Kogut N, Palmer J, Gaal K, Kim Y, Bhatia R, Yuan S, Kay C, Weiss L, Forman S. Wang S, et al. Among authors: snyder d. Transfusion. 2007 Dec;47(12):2207-16. doi: 10.1111/j.1537-2995.2007.01448.x. Epub 2007 Aug 21. Transfusion. 2007. PMID: 17714420
Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia.
Stein AS, Palmer JM, O'Donnell MR, Kogut NM, Spielberger RT, Slovak ML, Tsai NC, Senitzer D, Snyder DS, Thomas SH, Forman SJ. Stein AS, et al. Among authors: snyder ds. Biol Blood Marrow Transplant. 2009 Nov;15(11):1407-14. doi: 10.1016/j.bbmt.2009.07.003. Biol Blood Marrow Transplant. 2009. PMID: 19822300 Free PMC article.
A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma.
Nademanee A, Forman S, Molina A, Fung H, Smith D, Dagis A, Kwok C, Yamauchi D, Anderson AL, Falk P, Krishnan A, Kirschbaum M, Kogut N, Nakamura R, O'donnell M, Parker P, Popplewell L, Pullarkat V, Rodriguez R, Sahebi F, Smith E, Snyder D, Stein A, Spielberger R, Zain J, White C, Raubitschek A. Nademanee A, et al. Among authors: snyder d. Blood. 2005 Oct 15;106(8):2896-902. doi: 10.1182/blood-2005-03-1310. Epub 2005 Jul 7. Blood. 2005. PMID: 16002426 Free PMC article. Clinical Trial.
High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A, Sniecinski I, Schmidt GM, Dagis AC, O'Donnell MR, Snyder DS, Parker PM, Stein AS, Smith EP, Molina A, et al. Nademanee A, et al. Among authors: snyder ds. J Clin Oncol. 1994 Oct;12(10):2176-86. doi: 10.1200/JCO.1994.12.10.2176. J Clin Oncol. 1994. PMID: 7523609 Clinical Trial.
High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors.
Nademanee A, O'Donnell MR, Snyder DS, Schmidt GM, Parker PM, Stein AS, Smith EP, Molina A, Stepan DE, Somlo G, et al. Nademanee A, et al. Among authors: snyder ds. Blood. 1995 Mar 1;85(5):1381-90. Blood. 1995. PMID: 7858268 Free article.
Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.
Nademanee A, Molina A, Dagis A, Snyder DS, O'Donnell MR, Parker P, Stein A, Smith E, Planas I, Kashyap A, Spielberger R, Fung H, Krishnan A, Bhatia R, Wong KK, Somlo G, Margolin K, Chow W, Sniecinski I, Vora N, Slovak M, Niland JC, Forman SJ. Nademanee A, et al. Among authors: snyder ds. Clin Lymphoma. 2000 Jun;1(1):46-54. doi: 10.3816/clm.2000.n.004. Clin Lymphoma. 2000. PMID: 11707813
Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed.
Fung HC, Cohen S, Rodriguez R, Smith D, Krishnan A, Somlo G, Sahebi F, Senitzer D, O'Donnell MR, Stein A, Snyder DS, Spielberger R, Bhatia R, Falk P, Molina A, Nademanee A, Parker P, Kogut N, Popplewell L, Vora N, Margolin K, Forman SJ. Fung HC, et al. Among authors: snyder ds. Biol Blood Marrow Transplant. 2003 Oct;9(10):649-56. doi: 10.1016/s1083-8791(03)00241-6. Biol Blood Marrow Transplant. 2003. PMID: 14569561 Free article. Clinical Trial.
A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome.
Fung HC, Stein A, Slovak Ml, O'donnell MR, Snyder DS, Cohen S, Smith D, Krishnan A, Spielberger R, Bhatia R, Bhatia S, Falk P, Molina A, Nademanee A, Parker P, Rodriguez R, Rosenthal J, Sweetman R, Kogut N, Sahebi F, Popplewell L, Vora N, Somlo G, Margolin K, Chow W, Smith E, Forman SJ. Fung HC, et al. Among authors: snyder ds. Biol Blood Marrow Transplant. 2003 Dec;9(12):766-71. doi: 10.1016/j.bbmt.2003.08.004. Biol Blood Marrow Transplant. 2003. PMID: 14677116 Free article.
1,229 results